Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 11, Issue 4, Pages 326-331Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2011.04.006
Keywords
-
Categories
Funding
- Academy of Finland
- Finnish Cancer Organisations
- Sigrid Juselius Foundation
Ask authors/readers for more resources
FK506 binding protein 51 (FKBP51, FKBP5) functions as a co-chaperone for androgen, glucocorticoid, mineralocorticoid and progesterone receptors. The FKBP51 can act as an important determinant of the responses to steroids, especially to glucocorticoids in stress and mood disorders and androgens in prostate cancer, raising medical and pharmacological interests in the protein and its gene. Recent studies have revealed the molecular mechanisms by which the androgens and the glucocorticoids via their nuclear receptors elicit the robust up-regulation of the FKBP51 gene. Several polymorphisms in the FKBP51 gene have been associated with the mood disorders and differences in glucocorticoid sensitivity. The polymorphisms may contribute to the steroid up-regulation of the FKBP51 and thus influence the regulatory loops in steroid signaling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available